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ABSTRACT The hepatitis C virus (HCV) E2 glycoprotein is a major target of the
neutralizing antibody (nAb) response, with multiple type-specific and broadly
neutralizing antibody (bnAb) epitopes identified. The 412-to-423 region can gen-
erate bnAbs that block interaction with the cell surface receptor CD81, with ac-
tivity toward multiple HCV genotypes. In this study, we reveal the structure of
rodent monoclonal antibody 24 (MAb24) with an extensive contact area toward
a peptide spanning the 412-to-423 region. The crystal structure of the MAb24 –
peptide 412-to-423 complex reveals the paratope bound to a peptide hairpin
highly similar to that observed with human MAb HCV1 and rodent MAb AP33,
but with a different angle of approach. In viral outgrowth experiments, we dem-
onstrated three distinct genotype 2a viral populations that acquired resistance to
MAb24 via N415D, N417S, and N415D/H386R mutations. Importantly, the MAb24-
resistant viruses exhibited significant increases in sensitivity to the majority of
bnAbs directed to epitopes within the 412-to-423 region and in additional anti-
genic determinants located within E2 and the E1E2 complex. This study suggests
that modification of N415 causes a global change in glycoprotein structure that
increases its vulnerability to neutralization by other antibodies. This finding sug-
gests that in the context of an antibody response to viral infection, acquisition
of escape mutations in the 412-to-423 region renders the virus more susceptible
to neutralization by other specificities of nAbs, effectively reducing the immuno-
logical fitness of the virus. A vaccine for HCV that generates polyspecific humoral
immunity with specificity for the 412-to-423 region and at least one other region
of E2 is desirable.
IMPORTANCE Understanding how antibodies neutralize hepatitis C virus (HCV) is es-
sential for vaccine development. This study reveals for the first time that when HCV
develops resistance to a major class of bnAbs targeting the 412-to-423 region of E2,
this results in a concomitant increase in sensitivity to neutralization by a majority of
other bnAb specificities. Vaccines for the prevention of HCV infection should there-
fore generate bnAbs directed toward the 412-to-423 region of E2 and additional
bnAb epitopes within the viral glycoproteins.
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Hepatitis C virus (HCV) infects 60 to 120 million people worldwide and causeschronic liver disease and hepatocellular carcinoma (1). HCV is an RNA virus of the
genus Hepacivirus of the Flaviviridae family and displays a high degree of genetic and
antigenic variability. As a result, HCV is classified into seven distinct genotypes that
differ by up to 30% at the nucleotide level and 67 confirmed subtypes that differ by up
to 20% at the nucleotide level (2). In addition, in infected people, the low-fidelity
RNA-dependent RNA polymerase creates HCV quasispecies (3) that are under selection
pressure via major histocompatibility complex restriction, T cell and antibody recogni-
tion, or antiviral treatment (4).
Entry of HCV into hepatocytes is mediated by viral glycoproteins E1 and E2, which
form heterodimers on the surface of the virions. The binding of E2 to host cell receptor
CD81 is an essential step in HCV entry; thus, HCV E2 is a major target of neutralizing
antibodies (nAbs). A recombinant form of E2 containing the N-terminal portion span-
ning residues 384 to 661 can be expressed independently of the remaining glycopro-
tein, resulting in the secretion of a receptor-binding domain (RBD) that retains CD81-
binding and key neutralization epitopes (5–7). Within the RBD are three variable
regions, hypervariable region 1 (HVR1; residues 384 to 410), HVR2 (residues 460 to 485),
and the intergenotypic variable region (igVR/VR3; residues 570 to 580).
Glycoprotein E2 is a target for the generation of nAbs. Two independently derived
core domain structures of HCV E2 show a central immunoglobulin-like -sandwich
flanked by front and back layers (8, 9). These E2 core domain structures lack three-
dimensional (3D) information for the N-terminal region (residues 384 to 419) that
includes HVR1; residues 452 to 492, which include HVR2; and the C-terminal region
beyond residue 645 (8). The contact area for interaction with CD81 and a number of
broadly neutralizing monoclonal antibodies (bnMAbs) reside on the so-called neutral-
izing face of E2, with HVR2 and the igVR located on the opposite “nonneutralizing” face.
HVR1 is immunodominant in natural infection, and antibodies directed to this epitope
can mediate the neutralization of autologous viral isolates and rapidly select escape
variants. Three additional regions within E2 have been identified as targets of bnAbs
and overlap regions involved in CD81 interactions, i.e., residues 412 to 423 (domain E,
epitope I, AS412), residues 434 to 446 (domain D, epitope II, AS434), and antigenic
region 3 (AR3), which comprises the entire front or neutralizing face of E2. In addition,
human bnMAbs have been isolated that are specific for epitopes that comprise the
E1E2 heterodimer and are referred to as AR4 and AR5 (10).
bnAbs toward the 412-to-423 region are infrequently elicited in natural HCV infec-
tion, being detected in only 2.5 to 15% of chronically infected people (11, 12). Within
this region, two amino acid residues, W420 and H421, are important for the binding of
E2 to CD81 (13, 14). Several bnMAbs targeting this region have been isolated from
rodents vaccinated with E2 antigens and from humans through natural infection,
including mouse AP33 (15–17), rat 3/11 (17, 18), human HCV1 and 95-2 (19), human
HC33.1 and related antibodies (12), H77.39 (20), MRCT10.v362 and hu5B3.v3 (21), and
MAb24 (7). As the 412-to-419 region is disordered in E2 core structures, structural
information on epitope I has only been obtained by using antibodies in complex with
synthetic peptides spanning the 412-to-423 region. These studies have revealed alter-
nate conformations of bnMAb-bound peptide: a -hairpin structure (AP33, HCV1,
MRCT10.v362, and hu5B3.v3), an extended structure (3/11), and a largely extended
structure containing a short three-residue -strand (HC33.1) (21–26). In addition, the
angle of approach is distinct, even for MAbs that bind their epitopes in very similar
conformations. The description of alternate conformations of the 412-to-423 region
may suggest that it displays conformational flexibility and could represent another
mechanism of immune evasion (22).
A vaccine that prevents new HCV infections is required to support disease elimina-
tion efforts. Such a vaccine ideally should generate bnAbs able to prevent infection by
all circulating genotypes and subtypes of HCV. Antibody specifcities targeting domain
E/epitope I (HCV1-like) are highly desirable components of the vaccinal immune
response. We showed previously that immunization of small animals with an RBD
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construct lacking the three variable regions (Δ123) led to the generation of domain
E/epitope I-targeted bnAbs that were effective against the six major HCV genotypes. It
is therefore essential to understand how HCV could escape domain E/epitope
I-targeting antibodies and the overall effect of escape mutations on virus fitness.
Previously, we described domain E/epitope I-specific murine monoclonal antibody 24
(MAb24), which was isolated from a mouse immunized with Δ123 from genotype 1a
H77c (7). The epitope of MAb24 is located in the 412-to-423 region of E2, and MAb24
prevents interaction with CD81 and has broad neutralization properties (7).
In this study, we further characterized the neutralization mechanism of MAb24 by
examining the dynamic evolution of HCV quasispecies (genotype 2a) in vitro under the
extreme selective pressure of MAb24 by the use of next-generation sequencing anal-
ysis. We found that resistance to MAb24 neutralization involves either a direct mutation
in its epitope (N415D) or a shift in glycosylation (N417S) that obstructs binding by
MAb24. In addition, we identify an additional mutation in HVR1 (H386R) that improves
the fitness of viruses containing the N415D mutation. Structural analyses showed that
an epitope I peptide bound to MAb24 adopts a -loop conformation but with an angle
of approach different from that of previously described antibodies. We show that
acquisition of these mutations results in viruses that are resistant to MAb24 and HCV1.
However, viruses containing N415D, N417S, or H386R/N415D have enhanced sensitivity
to neutralization by domain E/epitope I-specific HC33.1 and other bnMAbs targeting
epitopes outside this domain. Our findings suggest that acquisition of mutation(s)
N415D, N417S, or H386R/N415D does not confer fitness on HCV in the context of a nAb
response during infection. This study reinforces the notion that domain E/epitope I
specificities are highly desirable components of the vaccinal immune response to HCV.
RESULTS
HCV replication under the selective pressure of MAb24. To determine whether
HCV is able to escape MAb24 neutralization, extracellular G2a cell culture-produced
HCV (HCVcc), derived from transfection of cells with RNA of the wild-type (WT) JC1flag2
(p7-NS-GLUC2A) virus (JC1flag), was mixed with 0, 0.245, 0.98, or 9.8 g/ml MAb24,
which corresponds to the antibody concentration required to effect 0, 50, 70, or 90%
neutralization of the original viral stock, respectively, prior to the inoculation of Huh7.5
cells. The inoculated cells were cultured for 3 days in the presence of MAb24 prior to
passaging on naive Huh7.5 cells. To maximize the chance of selecting diverse escape
mutants, infected cells from each passage were included with corresponding culture
supernatants in the subsequent passage. The amount of MAb24 added to cultures was
progressively increased from passage 4 onward such that 2 times (passage 4), 5 times
(passage 5), 10 times (passage 6), or 20 times (passages 7 to 9) the original amount of
MAb24 was used. Within 27 days of culture, virus replication was detected at MAb24
concentrations 20 times the 90% inhibitory concentration (IC90), suggesting that highly
resistant viruses had been selected (Fig. 1A). Replicating virus was not recovered in a
parallel passaging experiment where only tissue culture fluid containing extracellular
virus was sequentially passaged on naive Huh7.5 cells in the presence of the concen-
trations of MAb24 described above, despite lengthening of the passage interval from
3 to 4 days (Fig. 1B). We confirmed that the passage 9 virus stock obtained as shown
in Fig. 1A was able to infect naive Huh7.5 cells and replicate in the absence of MAb24.
Neutralization assays confirmed that the passage 9 virus stock is resistant to MAb24,
whereas the virus recovered at passage 9 passaged in the absence of MAb24 remained
sensitive to neutralization by MAb24 (Fig. 1C). Together, these findings indicate that
HCV is able to generate MAb24-resistant variants within 27 days in vitro.
Characterization of MAb24-resistant quasispecies. To identify mutations associ-
ated with resistance to MAb24 neutralization in the infected cell passaging experiment,
cDNA was prepared from passage 9 extracellular HCVcc where the starting (time zero)
concentration of MAb24 was 9.8 g/ml. Sanger sequencing of the complete E1E2
region showed that single adaptive mutations accumulated in the E2 epitope I region
(residues 412 to 423), at position N415 (43%) or N417 (21%). In addition, 29% of the
Neutralization Escape by Hepatitis C Virus Journal of Virology
May 2018 Volume 92 Issue 9 e02066-17 jvi.asm.org 3
 on A






















clones isolated contained both N415D and an additional mutation in HVR1, H386R
(Fig. 2). Dominant mutations were not found in E1 or elsewhere in E2 by this method
(not shown). These mutations were not present in cDNA prepared from HCVcc isolated
after nine passages in the absence of MAb24 (data not shown), indicating that they
arose because of MAb24 selection.
Illumina high-throughput sequencing was used to further examine the in vitro
evolution of HCVcc toward MAb24 resistance. Barcoded primers were used to sequence
cDNA prepared from cell-free HCVcc and HCVcc extracted from cell lysates, targeting
the region encompassing amino acids 410 to 550, which includes epitope I. Group-wide
comparison of virus sequences obtained at different time points and in the presence of
MAb24 showed single nucleotide polymorphisms (SNPs) generating mutations at
FIG 1 Generation of genotype 2a HCVcc MAb24 neutralization resistance variants. (A) At day 1, HCVcc,
produced by transfection of Huh7.5 cells, was incubated in the presence of MAb24. At day 3, cell-free virus,
together with infected cells from the passage, was added to naive Huh7.5 cell monolayers in the presence
of MAb24 and repeated every 3 days for a total of nine passages. The amount of MAb24 was progressively
increased, and the proportion of infected cells was gradually decreased at the passages indicated, as shown
at the top. Luciferase activity in the supernatant fluid (in relative light units [RLU]) was measured on the
days indicated. (B) At day 1, HCVcc, produced by transfection of Huh7.5 cells, was incubated in the presence
of MAb24, and at day 3, tissue culture supernatant fluid containing cell-free virus was applied to naive
Huh7.5 monolayers in the presence of MAb24; this was repeated for a total of seven passages, and the RLU
in the supernatant fluid were measured on the days indicated. (C) Virus harvested at passage 9 (P9) from
panel A cultured at a starting MAb24 concentration of 9.8 g/ml or cultured in the absence of MAb24 was
incubated with serial dilutions of MAb24 and added to naive Huh7.5 cells. Infectivity was measured 72 h
later. GND is a mutation in NS5B that renders HCVcc replication incompetent.
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amino acid residues N415 and N417, consistent with the Sanger sequencing results
(Table 1). N415D was the most common mutation observed; it was found in 27% of the
population at passage 7 and in 79% of the population at passage 9. Other variants at
the N415 position were also detected at passages 7 and 9, including N415S, N415T, and
N415G at a low frequency (1%). In addition, N417S was detected at a very low
frequency (1%) at passage 4, in 1% of the sequences at passage 7, and in 12% of the
sequences at passage 9. Traces of variants at V414 and G418 were also found at passage
7, but they remained at an extremely low frequency at passages 7 to 9. Additional
variants external to the MAb24 epitope were transiently observed at a frequency of
1% at I422, D431, I438, Y443, M456, E482, N534, and L541 in sequences obtained
between passages 4 and 7. Variants with P, V, and I at position L540 were observed at
a low frequency (1%) at passage 4 but did not increase in frequency over subsequent
passages. Greater than 99% of the sequences of HCVcc isolated in the absence of
MAb24 were those of the parental virus, confirming that mutations at positions N415
and N417 are selected by MAb24 (data not shown).
Characterization of viruses with N415D, N417S, and H386R/N415D mutations.
To further examine the effects of MAb24 resistance-conferring mutations on viral
fitness, the three most frequently occurring mutations in the viral quasispecies that
exhibited high levels of resistance to MAb24, N415D, N417S, and H386R/N415D, were
each reverse engineered into the parental JC1flag G2a genome. The replication and
FIG 2 Sanger sequencing of cDNA clones obtained following the generation of MAb24-resistant virus. cDNA was
prepared from viral RNA present in the supernatant fluid of infected cells at passage 9 and sequenced with BigDye
Terminator. The entire E1E2 region was sequenced, and the region where mutations were detected is shown
(residues 384 to 443).
TABLE 1 Frequencies of mutations in cell-free virus within the E2 region
WT residue
Mutation(s) (frequency [%]) at passage:a
0 4 7 9
V414 V (100) V (100) V (99), A (1) V (99), A (1)
N415 N (100) N (100) N (70), D (27), S (1), T (1), G (1) D (79), N (16), S (3), T (1), G (1)
N417 N (100) N (99), S (1) N (98), S (1) N (87), S (12)
G418 G (100) G (100) G (99), A (1) G (99), A (1)
I422 I (100) I (100) I (100) I (99), V (1)
D431 D (100) D (100) D (99), G (1) D (100)
I438 I (100) I (100) I (100) I (99), V (1)
Y443 Y (100) Y (99), H (1) Y (100) Y (100)
F447 F (100) F (100) F (100) F (99), L (1)
M456 M (100) M (99), V (1) M (100) M (100)
E482 E (100) E (100) E (100) E (99), G (1)
N534 N (100) N (100) N (99), S (1) N (99), D (1)
L540 L (100) L (98), P (1), V (1), I (1) L (99), P (1), V (1) L (99), P (1), V (1)
L541 L (100) L (100) L (99), S (1) L (100)
aExtracellular virus was obtained from the selected passage numbers from cultures of Huh7.5 cells initially infected with virus in the presence of 9.8 g/ml MAb24
with serial passage of infected cells and extracellular virus.
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infectivity of the three mutant viruses were characterized and compared with those of
the WT virus. All three viral mutants replicated at WT levels in cells transfected with the
viral genomic RNA (Fig. 3A). When the infectivity of the resultant cell-free viruses was
examined, small differences between the three mutants and the parental virus were
observed. The infectivity of HCVcc carrying the N415D mutation was reduced 6-fold
but was restored 3-fold when the H386R mutation was included. In contrast, the N417S
mutant virus was at least as infectious as the parental virus (Fig. 3B). These data suggest
that N415D is associated with a fitness cost but fitness is partially restored by the
addition of H386R, whereas no fitness cost is associated with the acquisition of N417S.
The differences in fitness between the N415D and N417S mutant viruses were further
examined by using a fluorescent-focus assay where the total number of NS5A-positive
foci and the number of positive foci containing two or more nuclei were enumerated
72 h postinfection with normalized amounts of viral inoculum. The results (Fig. 3C)
reveal that the N417S mutant is approximately 2-fold more infectious that the WT and
the N415D mutant and is likely to spread faster between apposed cells, as evidenced
by the greater proportion of foci containing two or more nuclei relative to the WT or
the N415D mutant. To confirm that the epitope I mutations are directly associated with
viral resistance to an epitope I-specific antibody, we examined their MAb24 neutral-
ization profiles. While the WT virus was readily neutralized by MAb24, virus containing
either N415D or N417S exhibited resistance to neutralization by MAb24, recapitulating
the phenotype observed at passage 9 (Fig. 3D).
Mutations conferring resistance to MAb24 result in an increase in sensitivity to
neutralization by other MAbs. To investigate whether mutations at H386, N415, and
FIG 3 Viruses with N415D, N417S, and N415D/H386R mutations are replication competent, infectious, and
resistant to MAb24 neutralization. (A) RNA was prepared from reverse-engineered HCVcc containing
mutations Asp415, Ser417, and Arg386/Asp415 and transfected into Huh7.5 cells. Luciferase activity was
measured in the supernatant fluid every 24 h. RLU, relative light units. (B) Supernatant fluid was collected
72 h after RNA transfection into Huh7.5 cells, normalized for infectivity, and used to infect naive Huh7.5 cell
monolayers. Luciferase activity was measured in the supernatant fluid every 24 h. (C) Normalized amounts
of HCVcc were added to naive Huh7.5 cells. After 72 h, monolayers were fixed and stained with antibody
to NS5A and counterstained with propidium iodide and the number of nuclei per focus was determined.
Data are representative of two independent experiments performed in duplicate. (D) Reverse-engineered
viruses with N415D and N417S were incubated with serial dilutions of MAb24 and applied to naive Huh7.5
cell monolayers. Luciferase activity in the supernatant fluid was measured at 72 h postinfection. Graphs
were drawn in Prism v7 by using nonlinear regression.
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N417 affected neutralization by other bnMAbs specific to this region and MAbs whose
epitopes lie elsewhere in E2, we performed neutralization assays with previously
well-characterized human bnMAbs. We first examined neutralization by other bnMAbs
that also recognize epitopes in the 412-to-423 region (HCV1, HC33.1). Genotype 2a
HCVcc with N415D, N417S, or the H386R/N415D double mutation is resistant to
neutralization by HCV1, which recognizes its epitope within the 412-to-423 region in a
hairpin conformation (24). HC33.1 is a bnMAb whose linear epitope is also contained
within the 412-to-423 region. However, an extended conformation of this epitope is
observed when it is bound to HC33.1 (25). In contrast to the data obtained with MAb24
and HCV1, N415D, N417S, and H386R/N415D mutant viruses were significantly more
sensitive to HC33.1 neutralization than the WT was (Fig. 4 and Table 2).
FIG 4 Neutralization of HCVcc with N415D, N417S, and H386R/N415D mutations by human MAbs. Serial dilutions of each MAb were
incubated with parental HCVcc (WT) or N415D, N417S, or H386R/N415D mutant virus. After 72 h, the luciferase activity was measured. Data
shown are the mean of at least three independent experiments performed in triplicate, with the exception of AR5A, which was performed
once in triplicate. Neutralization curves were drawn by nonlinear regression analysis (Prism v7) and used to obtain IC50s (Table 2).
TABLE 2 Susceptibility of HCV to neutralization by MAbsa
a(1) Data are the mean values of at least three experiments calculated from the data shown in Fig. 4 by
using the log inhibitor versus normalized response curve in Prism v7.0. The symbol  indicates that the
amount of antibody required to inhibit entry is greater than the highest concentration tested. Red indicates
significantly more resistance than the parental WT virus (P  0.001). Dark green and light green indicate
significantly more sensitivity to neutralization than the parental WT virus (P  0.001 and P  0.004 to
0.007, respectively). White indicates no significant difference from the parental WT virus (P  0.05). (2) The
IC50 (g/ml) of each MAb for the WT virus and fold changes in IC50 relative to the WT virus are shown. (3)
NC, not converged (no P value calculated). Red, fold increase in resistance; green and white, fold increase in
sensitivity.
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The HCVcc variants were next tested with a panel of E2-specific human bnMAbs that
are directed to epitopes outside the 412-to-423 region. The bnMAb panel included
HC84.1 and HC84.27 directed to the 430-to-451 region (domain D, epitope II, or AS434)
(27) and bnMAbs that bind discontinuous sequences in domain B (CBH-2, epitope
contains CD81 binding loop residues 519 to 535, CBH-5), domain C (CBH-7, epitope
includes N540 and W549) (28, 29), AR3 (AR3C), AR4 (AR4A), and AR5 (AR5A) (10). In
almost all cases, N415D, N415D/H386R, and N417S mutant viruses were significantly
more sensitive to neutralization by these bnMAbs than the parental (WT) virus was. The
exceptions were the N417S mutant with CBH-7 and the N415D mutant with AR5A.
These results suggest that the acquisition of resistance to MAb24 via mutations in the
412-to-423 region results in a global shift in neutralization sensitivity toward other
bnMAbs recognizing distinct epitopes in E1E2.
E2 epitope I adopts a -hairpin conformation when bound to MAb24. To
understand the structural basis of MAb24 binding to E2, we determined the crystal
structure of the antigen-binding fragment (Fab) of MAb24 in complex with a peptide
from E2 epitope I corresponding to residues 412 to 423. When in complex with MAb24,
epitope I is in a -hairpin conformation (Fig. 5 and Table 3). This conformation differs
markedly from the extended conformations observed with MAbs HC33.1 (25) and 3/11
(22) (Fig. 5 and 6A and B), which reinforces the notion that epitope 1 is highly
conformationally flexible and yet antibodies to all known conformations possess broad
neutralization activity against HCV isolates. Two other antibodies recognize epitope 1
in a similar hairpin conformation: human-derived HCV1 (24) and rodent-derived AP33
(16, 23, 26). The peptide adopts very similar conformations in all three structures with
all-atom root mean square deviations (RMSDs) of 1.26 and 1.45 Å for AP33 and HCV1,
respectively. However, recognition differs by the angles of approach. AP33 and MAb24
have similar angles of approach related by a 4.1° rotation around the peptide (Fig. 6C
and D), while the orientation of HCV1 is drastically different (Fig. 5, 31.3° rotation). Thus,
a different footprint on the intact E2 protein is anticipated. The RMSDs between Calpha
atoms of MAb24 Fab with AP33 and HCV1 are 0.65 and 3.49 Å for 418 and 387
equivalent residues, respectively.
FIG 5 Epitope 1, represented as a green ribbon, adopts a -hairpin conformation when bound to MAb24
and HCV1 (PDB code 4DGY), in contrast to the extended conformations found in structures of HC33.1
(PDB code 4XVJ) and 3/11 (PDB code 4WHT). Note the difference in the angles of approach between
MAb24 and HCV1 evident from the shift of the heavy (brown) and light (blue) chains in this orientation.
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Tryptophan 420 is a major contributor to the recognition of E2 for all epitope
I-directed antibodies. In MAb24, this residue inserts itself deeply into the paratope and
forms extensive hydrophobic interactions with both the heavy and light chains of the
antibody (Fig. 6A and B). It also forms a hydrogen bond with the main-chain carbonyl
of N91 of the MAb24 light chain. The heavy-chain CDR3 and light-chain CDR1 residue
(Y28) form a clamp around the N and C termini of the peptide that appear to stabilize
the hairpin conformation (Fig. 6B). Two other features may also favor a hairpin
conformation: (i) Y33 and Y50 on the heavy chain, which make multiple hydrogen
bonds with the main chain of the first strand of the peptide, and (ii) intrapeptide
hydrogen bonding between the side chains of H421 and T416 that staples the two
strands together. The requirement of H421 and T416 for MAb24 binding was confirmed
in previous alanine substitution studies of the 412-to-423 region (7).
The intrapeptide interaction is not found in the high-resolution structure of AP33
epitope I (Fig. 6E and F, PDB code 4GAG), but it is present as an alternate conformation
in a lower-resolution complex of AP33 with a slightly different peptide (PDB code 4GAJ)
and in HCV1. Although the paratope surfaces of MAb24 and AP33 are very similar, their
respective heavy-chain CDR3s differ in sequence and structure (Fig. 6E to G). In MAb24,
interactions are mediated primarily by the main chain of CDR3H, while the side chain
of Y100 forms the equivalent interacting surface in AP33. These differences in CDR3H
result in a tighter clamp in MAb24, including main-chain interactions by residue G101
(Fig. 6E and F).
TABLE 3 Data collection and refinement statisticsa
Parameter
Value at:
Total resolution Low resolution High resolution
Resolution range (Å) 19.91–1.40 19.91–1.76 1.45–1.40
Completeness (%) 69.1 98.1 15
I/I 33.5 42.5 3.4
CC1/2 (%) 100 100 89.5
Redundancy 2 2 1.9
Rmerge 0.01 0.009 0.202
Rmeas 0.015 0.013 0.285
Rpim 0.01 0.009 0.202
Refinement statistics
Resolution (Å) 1.4













Bond length (Å) 0.5
Bond angle (°) 0.68





aStatistical analysis was performed using XDS (42), BUSTER (46), CCP4 (52), and MolProbity (53).
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FIG 6 Recognition of E2 epitope I by MAb24. (A) Crystal structure of epitope I peptide E2412-423 (green) bound to the Fab of MAb24.
The heavy and light chains are brown and light blue, respectively. Side chains of MAb24 within 4 Å of epitope I are shown as sticks. (B) Diagram
of the interactions between epitope I (stick-and-ball representation) and MAb24. Hydrogen bonds are shown as green dotted lines, and Van der
Waals contacts are shown as red arcs. Residues from epitope I and the light and the heavy chains are labeled P, L, and H, respectively.
Intramolecular contacts are omitted. Residues contacting W420 of epitope I are shaded in blue. (C) Wall-eyed stereo view of epitope I peptides
from MAb24 (white) and AP33 (orange; PDB code 4GAG) structures. (D) Wall-eyed stereo comparison of the orientation of MAb24 (blue/brown)
and AP33 (magenta) with regard to epitope I. The respective epitope I chains were used for alignment of the complexes. (E, F) Orthogonal views
of the paratopes of MAb24 (E) and AP33 (F). The representation scheme is the same as in panel A omitting the molecular surface. The CDR3s of
(Continued on next page)
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Structural basis of the impact of MAb24 escape mutations. The impact of the
two mutations that enable MAb24 escape were modeled. Mutation N415D modeled in
the hairpin conformation of epitope I places the aspartic acid side chain in a pocket of
the paratope, which would bury 100% of its accessible surface. However, the paratope
is largely electronegative and the introduction of the deprotonated D415 residue
would create repulsive interactions, making it incompatible with binding (Fig. 7A and
B). AP33 also has an electronegative surface facing residue 415 of E2 (Fig. 7C), while
HCV1 presents a hydrophobic patch including the side chain of residue W94 in the light
chain (Fig. 7D).
The second escape mutation, N417S, results in the shift of a glycan from position
417 to position 415 (Fig. 7E and F). The 415 site is predicted by in silico glycosylation,
and biochemical evidence has been reported previously (30). The glycan at position
N417, while not essential for the infectivity in genotype 2a viruses (31), is essential for
viral entry in the context of genotype 1a HCV pseudoparticles (30). N415 glycosylation
results in a steric clash with MAb24, regardless of the conformation of the glycan chain,
since the base of the glycan directly faces the paratope (Fig. 7F). Thus, the glycan shift
alone explains the ability of N417S mutants to escape MAb24 neutralization. In contrast,
the presence of a glycan at position 415 does not present steric clashes that may impair
ligand formation with antibodies recognizing epitope I in an extended conformation
(Fig. 7G and H). The modeled glycan chain is positioned over a groove between the
heavy and light chains of HC33.1, which may provide additional favorable interactions
with the antibody.
Overall, both mutations N417S and N415D render the virus more sensitive to
HC33.1, which recognizes an extended conformation of epitope I, suggesting that
FIG 6 Legend (Continued)
the heavy chains bearing most of the differences between the antibodies are labeled CDR3H. (G) Comparison of contact residues between heavy-
and light-chain CDRs with peptide between MAb24 and AP33. All contacts within 4 Å are shown. Differences between AP33 and MAb24 are red.
The image shown was adapted from reference 23.
FIG 7 Structural impact of mutations at positions 415 and 417 on the recognition of epitope I. (A, B) Electrostatic surface of MAb24. The N415D mutation is
modeled and shown in cyan. The peptide is shown as a green ribbon over the molecular surface of MAb24 colored according to its electrostatic potential. The
red-white-blue ramp shows a scale of 2 to 2 kT. (C, D) Electrostatic surface of AP33 (C) and HCV1 (D) showing that N415 (cyan) faces W94 of the light chain,
which is highlighted in magenta. (E) Epitope I of the MAb24-sensitive strain shown as a ribbon with a modeled basic glycan at position 417 (cyan) represented
as spheres. (F) Epitope I of a MAb24-resistant strain bearing the N417S mutation modeled with a basic glycan at position 415 (cyan). (G, H) Orthogonal views
of the N417S mutant in complex with HC33.1. A glycan is modeled at position N415 and is shown as cyan spheres.
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either N415D or N417S may promote and/or stabilize an extended epitope I confor-
mation, as depicted in Fig. 8. This conformational shift has an impact on antigenic
regions distal from epitope I, enabling enhanced neutralization by human MAbs AR3C,
CBH-5, and CBH-7 targeting the front face of E2, domain B, and domain C, respectively;
MAbs HC84.27 and HC84.1 targeting domain D; and AR4A and AR5A targeting anti-
genic domains spanning the E1E2 complex.
DISCUSSION
Direct-acting antivirals (DAAs) have an enormous potential to reduce the number of
people infected with HCV, but major challenges remain regarding access to treatment,
their high cost, the need to identify people who have active HCV infection, and the
possibility of reinfection that will continue to drive the epidemic. The development of
a vaccine that prevents primary infection and reinfection with HCV remains a priority
and would substantially improve the effectiveness of DAAs and accelerate efforts to
reach elimination targets set by the World Health Organization. The study of antibody
responses to HCV envelope proteins both in natural infection and through vaccination
of experimental animals has advanced our understanding of the mechanisms of
neutralization and desirable antibody specificities that a vaccine should elicit.
The emerging model of glycoprotein E2 is one of a highly conformationally flexible
protein that employs multiple immune evasion mechanisms to restrict the generation
of bnAbs. The ability to delete all three variable regions and the C-terminal stalk
(residues 643 to 711) without significant alteration of the overall conformational
flexibility suggests that none of these regions contribute significantly to stabilization of
the core domain of E2 (32, 33). Interestingly, over 62% of the structure of the E2 core
domain structure was either in loops or was disordered, including residues 412 to 420
and 454 to 491, a loop at residues 585 to 596, and numerous N-linked glycans (8). In
addition, the entire front layer of E2 containing the CD81 binding site and the majority
of nAb epitopes is highly flexible (33). This level of conformational flexibility is analo-
gous to that observed in HIV gp120 and represents a novel mechanism employed by
highly variable viruses to suppress the production of nAbs by limiting the engagement
with B cell receptors.
Multiple MAbs that target the 412-to-423 region have been isolated from humans
naturally infected with HCV, as well as from animals vaccinated with E2-containing
immunogens. While high-resolution structures of E2 in complex with these antibodies
are not available, the structures of MAbs in complex with synthetic peptides have been
solved and reveal that this region can adopt multiple conformations (7, 12, 15-21). In
FIG 8 Models of the proposed interaction of epitope I, HVR1, and other antigenic regions. (A, B)
Mutations in epitope I increase the sensitivity to MAbs targeting epitope I itself (blue; MAb HC33.1) and
remote antigenic regions such as domain C (cyan; CBH-7), E2 components of AR5 (red; AR5A), domain D
(yellow; HC84.1 and HC84.27), and the CD81 binding loop comprising part of domain B (green; CBH-5).
The gray ellipse and arrows represent HVR1 and epitope I, respectively, in the MAb24-sensitive (left) and
MAb-resistant (right) viral strains.
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addition, electron microscopy reveals that one antibody to this region can have a 10 to
22° difference in the angle of approach to the E2 core domain (33). The conformational
flexibility of this region is reflected by the absence of electron density in the two
available E2 core domain structures. The ability to exist in multiple conformational
states has been proposed to be an additional mechanism of immune evasion to
maintain the subdominance of nAb epitopes in E2 (25, 33).
MAb24 was isolated by vaccinating mice with a minimized form of the E2 core
domain lacking all three variable regions and truncated at residue 661 derived from
genotype 1a prototype strain H77 lacking HVR1, HVR2, and the igVR. While MAb24 has
the ability to neutralize all seven genotypes of HCV, the IC50s vary widely, even for
identical sequences of the MAb24 epitope, which indicates a role for the regions
surrounding epitope I in the 3D structure of E2 (7). Specifically, HVR1 preceding epitope
I interacts with HVR2 and igVR, which are distant in the primary sequence and absent
from existing crystal structures (7, 34). The ability of MAb24 to inhibit CD81 binding to
Δ123 was 20-fold improved relative to that seen with intact E2, suggesting that the
three variable regions alter the exposure or conformation of the MAb24 epitope,
modulating epitope binding and subsequent CD81 blockade. Growth of genotype 2a
viruses in the presence of increasing concentrations of MAb24 in addition to passaging
of infected cells and cell-free virus resulted in the selection of escape variants that
either contain a mutation in a contact residue at N415 to aspartic acid or contain a
mutation that results in a shift of the N-linked glycan at position 417 to 415 (N417S). In
the experiments performed here, we additionally detected viruses that contain N415D
together with H386R in HVR1. Genotype 2a virus reverse engineered to contain N415D,
N417S, or N415D/H386R is highly resistant to neutralization by MAb24. Acquisition of
N415D results in a 6-fold reduction in the infectivity of genotype 2a viruses, but it is
restored in viruses containing N415D/H386R, suggesting that H386R is a compensatory
mutation that restores infectivity to WT levels.
The structure of residues 412 to 423 in complex with MAb24 reveals a -hairpin
conformation similar to that recognized by HCV1 and AP33. Mutation of N417 to Ser
results in a glycan shift to N415 that sterically precludes binding of antibodies to the
hairpin conformation of epitope I and explains how this mutation prevents neutraliza-
tion by MAb24. Despite this ability to confer resistance to HCV1-like antibodies,
examination of 7,486 sequences in the Los Alamos Database reveals that only 62
sequences contain a shift in glycosylation from 417 to 415, suggesting that this
mutation is rare (0.1%), whereas 5% of the sequences contain mutations at N415.
This low frequency of mutations at positions 415 and 417 may result from a fitness cost
for some genotypes. It is possible that mutations other than N415D, such as N415H/
K/R/Y observed in naturally occurring variants, do not confer the same phenotype as
that conferred by N415D. We attempted to introduce N415D and N417S mutations into
the genotype 1a H77c isolate, but viruses were not infectious, suggesting that addi-
tional compensatory mutations may be required to support replication in cell culture
(data not shown). However, these mutations were selected in genotype 1a H77
HCV-infected chimpanzees given 250 mg/kg HCV1 therapeutically, possibly suggesting
that these mutations confer in vivo viral fitness (35).
For genotype 2a, the N417S mutation has no fitness cost and the N415D mutation
is compensated for by the H386R mutation in HVR1. Another explanation for the low
frequency of MAb24 escape mutations is that they do not prevent neutralization by
antibodies recognizing an extended conformation of epitope I. Accordingly, modeling
shows that glycan shifting from N417 to N415 is tolerated by HC33.1 where the new
glycan extends outside the paratope. Indeed, a reverse-engineered genotype 2a virus
containing N415D, N417S, or N415D/H386R was more easily neutralized by HC33.1 than
the WT was, with a 5-, 3-, or 2-fold reduction in the amount of HC33.1 required to obtain
50% neutralization, respectively. It is possible that the introduction of N415D, or shifting
of the glycan from N417 to N415, may favor an extended conformation, thus enhancing
recognition by HC33.1-like antibodies in infection.
In addition, a more extensive analysis of neutralization by a broad range of other
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bnAbs to multiple antigenic regions of E2, including AS434 and AR3, as well as epitopes
that involve a heterodimer of E1 and E2 (AR4 and AR5), reveals that MAb24 escape
mutants are also more sensitive to neutralization by antibodies that recognize epitopes
external to epitope I. This suggests that the N415D and N417S mutations may result in
a global change in glycoprotein structure distal to epitope I, for example, through
relocalization of HVR1, increasing the accessibility of other antigenic regions. Changes
in HVR1 in the N415D mutant are further supported by the compensatory effect of
mutation H386R in this region.
If the N415D and N417S mutations that elicit region 412-to-423-directed nAbs were
selected in HCV-infected people, escape variants would be more susceptible to neu-
tralization by other bnAbs and would therefore have a replicative disadvantage under
immune pressure. These results suggest that vaccines that generate region 412-to-
423-directed nAbs are highly desirable but should be accompanied by at least one
other bnAb with specificity to an alternative bnAb epitope or an HC33.1-like
specificity. Recently, we published the findings of a vaccination study performed
with guinea pigs and Δ123, and reported broad and potent neutralization with
antibody specificities detected toward the 412-to-423 region and AR3, suggesting
that such antibody specificities can be induced by recombinant E2 vaccines (36).
Our findings further advance efforts toward the production of prophylactic HCV
vaccines that will be essential to support the elimination of hepatitis C as a public
health threat.
MATERIALS AND METHODS
Cell culture and antibodies. Human hepatocellular carcinoma cell line Huh7.5 was described
previously (37), and cells were kindly provided by Charles Rice (Rockefeller University, USA). They were
maintained in Dulbecco’s modified Eagle medium (DMEM; Invitrogen) supplemented with 10% fetal
bovine serum, 2 mM L-glutamine, 16.8 mM HEPES buffer, 40 g/ml gentamicin, 1 g/ml minocycline, and
nonessential amino acids (DMF10NEA).
Human MAbs CBH-2, CBH-5, and CBH-7 were kindly provided by Steven Foung. Mouse anti-NS5A
antibody 9E10 was a kind gift from Charles Rice. Human MAbs AR4A and AR5A were kindly provided by
Mansun Law. The expression vectors for human MAbs HC84.1 and HC84.27 were described previously (7).
Similarly, the heavy- and light-chain expression vectors for HCV1, HC33.1, and AR3C were constructed by
synthesizing their variable heavy- and light-chain sequences according to their PDB information (4DGY,
4XVJ, and 4MWF, respectively) and subcloning them into vectors pcDNA3-tPA-LC and pcDNA3-tPA-HC.
MAbs HCV1, HC33.1, AR3C, HC84.1, and HC84.27 were expressed in Freestyle 293F cells (Thermo Fisher
Scientific, Australia) and harvested after 7 days of culture. MAb24 was produced by a mouse hybridoma
cell line as previously described (7). The IgG was affinity purified with protein G Sepharose (GenScript,
USA), eluted with 100 mM glycine (pH 2.8), and then neutralized with 1 M Tris-HCl (pH 8.0). The eluted
IgG was dialyzed in phosphate-buffered saline (PBS), concentrated with Amicon Ultra Centrifugal Filter
Units (10-kDa cutoff; Merck Millipore, Australia), and filtered via a 0.45-m filter. Antibody concentration
was determined by measuring the absorbance at 280 nm with a NanoDrop spectrophotometer (Thermo
Fisher Scientific, Australia).
Vectors and mutagenesis. The DNA vector pJC1flag2 (p7-NS-GLUC2A) (JC1flag) was a kind gift from
Charles Rice (38). The identified resistant mutations N415D and N417S were introduced into JC1flag DNA
with the QuikChange II XL site-directed mutagenesis kit (Agilent, USA) in accordance with the manu-
facturer’s instructions. The mutated and amplified constructs were digested with BsiWI and BglII and
subcloned into similarly digested pJC1flag2. The DNA sequences were confirmed by using Applied
Biosystems PRISM BigDye Terminator chemistry (version 3.1). The H386R/N415D double mutant was
constructed by introducing the H386R mutation into a JC1flag construct containing N415D by the same
procedure.
Production of HCVcc. Vector JC1flag DNA or JC1flag mutant DNA was linearized with XbaI and
transcribed into RNA in vitro with the AmpliScribe T7 Flash Transcription kit (Epicentre, USA) before
purification with the Qiagen RNeasy minikit (Qiagen, Germany). To produce HCVcc, viral RNA was
transfected into Huh7.5 cells preseeded at 3.5  105/well into six-well plates with DMRIE-C transfection
reagent (Life Technologies, USA) in accordance with the manufacturer’s recommendation. Alternatively,
it was produced by electroporation of the RNA into Huh7.5 cells in T175 flasks. Three days after
transfection, virus-containing cell culture supernatant was harvested and precleared before storage at
80°C.
Virus passaging. To investigate whether HCV can escape MAb24 neutralization, HCVcc produced by
transfecting pJC1flag RNA was passaged in the presence of various concentrations of MAb24 in 24-well
plates. The IC50, IC70, and IC90 of MAb24 against the starting HCVcc were first determined (0.245, 0.98, and
9.8 g/ml, respectively). At time zero, HCVcc was incubated with 0, 0.245, 0.98, or 9.8 g/ml MAb24 IgG
for 1 h at 37°C before addition to a monolayer of naive Huh7.5 cells used to preseed 24-well plates at
4  104/well. After 4 h, the medium was replaced with DMF10NEA containing MAb24 at the corre-
sponding concentration. Cell culture supernatant was monitored for luciferase activity with the Renilla
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luciferase assay system (Promega, USA) and a FLUOstar OPTIMA reader fitted with luminescence optics
(BMG Lab Technologies GmBH, Germany). This was repeated every 4 days. Alternatively, HCVcc was
neutralized with MAb24 and passaged with infected cells at 3-day intervals. In addition to MAb24
neutralization at 37°C for 1 h and the addition of an extracellular HCVcc-MAb24 mixture to naive Huh7.5
cell monolayers (preseeded at 2.5  104/well), the infected Huh7.5 cells from the previous passage were
trypsinized and a fraction was added to the naive Huh7.5 cells. Renilla luciferase activity in the cell culture
supernatant was as indicated. The concentration of MAb24 was increased to 2 times (passage 4), 5 times
(passage 5), 10 times (passage 6), and 20 times (passage 7 onward) the corresponding starting
concentration. The proportion of infected Huh7.5 cells added in each round of passage was reduced from
10% (passage 1) to 5% (passage 6) and 4% (passage 7 onward). The extracellular HCVcc and intracellular
HCVcc (in infected cells) were collected at the end of each passage and stored at 80°C.
Virus sequencing. Viral RNA was extracted from the cell culture supernatant with the QIAamp Viral
RNA minikit (Qiagen, USA). The E1E2 or E2 region was amplified with the SuperScript III one-step reverse
transcription-PCR system with Platinum Taq High Fidelity (Invitrogen, USA). The resulting cDNA was
cloned into the pGEM-T or pGEM-T Easy vector (Promega, USA), and clones were sequenced by using
Applied Biosystems PRISM BigDye Terminator chemistry (version 3.1).
Next-generation sequencing. The primer design was as described in reference 39, in which a
random eight-nucleotide tag (barcode) is inserted after the target sequence with the 5= addition of a
nonspecific sequence to allow amplification by PCR (5=-ACCTTGCAAGCACGCTCTGGCCTTGAANNNNNN
NNCTTAAGC[barcode]CAGCGGTGGTCGAGTGCTGTTCAATAG-3=) corresponding to a specific primer ID.
Primers were synthesized (Integrated DNA Technologies, USA). Accordingly, each cDNA template was
synthesized with a unique primer ID (barcode tag), allowing accurate estimation of the viral species in
the sample pool and the elimination of PCR artifacts in the analysis pipeline (40). Following cDNA
synthesis, the reaction product was treated with RNase H (Invitrogen, USA) and purified with AMPure XP
(Agencourt, Beckman Coulter).
The cDNA template was amplified by nested PCR with PrimeSTAR GXL DNA polymerase (Clontech,
TaKaRa) in a 20-cycle first-round reaction, followed by a 25-cycle second-round nested reaction. The
primers used to amplify the first-round product were 5=-TACAAGGACGACGACGACAAGGGC-3= (sequence
of the flag tag within JC1) and the 5= portion of the primer used in the cDNA reaction mixture,
5=-ACCTTGCAAGCACGCTCTGGC-3=. The primers used to amplify the first-round template in a nested
PCR were 5=-GCGCCTCACCAGCTTATTT-3= (H77 reference position 1532) and 5=-CAAGCACGCTCTGG
CCTTGAA-3=.
Amplicons were pooled in equimolar ratios and used as the input for library preparation with the
Kapa Hyper Prep library kit in accordance with the manufacturer’s protocol (Kapa Biosystems, Inc.,
Wilmington, MA, USA). Postquantitation of these library preparations was performed with the Kapa
library quantitation kit (Kapa Biosystems, Inc., Wilmington, MA, USA), and they were sequenced on the
MiSeq sequencer with the 600V3 kit (Illumina Inc., San Diego, CA) in accordance with the manufacturer’s
instructions. The data generated from the sequencing run were processed as follows. Sequence reads
were aligned with the J6 reference sequence and the primer ID by pairwise alignment. Sequence reads
that did not end with the primer ID sequence pattern were discarded. Reads were trimmed so that only
sequences corresponding to the region of interest were included. A “majority rules” consensus was
determined for each primer ID (minimum of three reads). The median number of unique primer IDs in
the samples was 331 (interquartile range, 161 to 484). SNP reports were generated with the proprietary
genome analysis tool VGAS.
Virus infectivity and immunofluorescence. Huh7.5 cells were used to preseed 24-well plates at a
density of 6  104/well on coverslips pretreated with 0.01% poly-L-lysine. Virus was diluted and allowed
to infect cells for 4 h before replacement with fresh medium. Renilla luciferase activity was measured at
24, 48, and 72 h postinfection. To visualize the level of infectivity, infected cells were washed and fixed
with ice-cold 100% methanol before blocking with 3% fetal bovine serum for 1 h at room temperature.
Infected cells were detected with anti-NS5A antibody 9E10 at 1:3,000, followed by an Alexa Fluor
488-conjugated goat anti-mouse IgG secondary antibody at 1:3,000 (Invitrogen, USA). Cell nuclei were
counterstained with propidium iodide for 5 min in the dark. Slides were mounted with coverslips and
examined with an Olympus IX50 inverted microscope.
Neutralization assays. Huh7.5 cells were used to preseed 96-well plates at 6  103/well. Antibodies
were serially diluted with DMF10NEA before incubation with a constant amount of virus for 1 h in
triplicate as described previously (36). The mixture was then added to the cells and incubated for 4 h
before replacement with fresh medium. Cell culture supernatant was lysed after 72 h, and luciferase
activity was measured. Assays were performed at least three times, except where indicated, and data
were analyzed with Prism (v7.0) by using nonlinear regression analysis to determine the IC50s.
Structural determination of MAb24 Fab in complex with a synthetic peptide spanning residues
412 to 423. Briefly, the MAb24 IgG was digested in immobilized papain resin for 3 h at 37°C before
purification on a protein A column and concentration and buffer exchange into PBS by using Amicon
Ultra Centrifugal Filter Units (3-kDa cutoff; Millipore, USA). The cleavage of MAb24 IgG into Fab was
confirmed by 10% SDS-PAGE and visualization by Coomassie blue staining.
Protein crystallization and structure determination. The purified Fab of MAb24 was concentrated
to 6.5 mg · ml1 and allowed to form a complex with the epitope I peptide (QLINTNGSWHVN,
synthetically produced; GenScript, China) at a 1:5 molar ratio at 4°C for 2 h. Crystallization screening was
performed with a Rigaku CrystalMation robotic system and Intelliplate 96-well crystallization plates. The
reservoir volume was 50 l, and sitting drops contained 100 nl of protein solution and 100 nl of
precipitant. Hits were obtained in a PEG Ion HT crystallization screen (Hampton Research). Initial hits were
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optimized by the hanging-drop method with 2-l drops and 1 ml of precipitant in each well. Small
crystals were obtained in a drop containing 11.4 mg · ml1 MAb24, 12.5% polyethylene glycol 3000 (PEG
3000), 100 mM NaCl, and 100 mM sodium phosphate dibasic/citric acid (pH 6.2). Addition of NaCl to the
reservoir to a final concentration of 0.5 M was used to further increase the protein concentration in the
crystallization drops, resulting in the formation of a hexagonal crystal within 48 h. The crystal was
cryoprotected by brief immersion in a mixture of 20% glycerol, 12.5% PEG 3000, 0.5 M NaCl, and 100 mM
sodium phosphate dibasic/citric acid (pH 6.2) before flash-cooling in liquid nitrogen.
Diffraction data were collected at a temperature of 100 K and an energy of 13,000 keV at the MX1
beamline of the Australian Synchrotron (41). Diffraction images were processed with XDS (42) and
POINTLESS (43). The crystal belonged to space group I2 with unit cell parameters of a  70.38 Å, b 
53.34 Å, c  133.90 Å,     90°, and   93.52°.
Structure determination, refinement, and analysis. The structure was determined by molecular
replacement with Phaser (44) and the Phenix suite (45) by using the AP33 antibody (PDB code 4GAG) as
an initial model (23). The model was refined with BUSTER (46) and built with Coot (47). LIGPLOT (48) was
used to represent the van der Waals contacts and hydrogen bond interactions between the peptide and
the antibodies. PyMOL (The PyMOL Molecular Graphics System, version 1.8; Schrödinger, LLC) was used
to render images of the structure. The surface potential and electrostatics were calculated with the
adaptive Poisson-Boltzmann solver (49). The binding surfaces were calculated by using the Proteins,
Interfaces, Structures, and Assemblies server (50). Glycans were modeled by using the in silico glycosy-
lation server GlyProt (51).
Accession number(s). Coordinates and diffraction data have been deposited in the Protein Data
Bank under accession no. 5VXR.
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